SynopsisIpatasertib is an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. The global Ipatasertib market was valued at US$ million in 2023 and is anticipated to reach US$ million .....
SynopsisIdelalisib is a kinase inhibitor. In combination with rituximab, it was used for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL). The global Idelalisib (CAL-101) market was valued at US$ million in 2023 and is anticipated to re.....
Synopsis2-Methyl-2-Pentenoic Acid is a carboxylic acid with the molecular formula C6H10O2, it is found in nature and has a sour, acidic, fruity, jammy, woody-like odour. The global 2-Methyl-2-Pentenoic Acid market was valued at US$ million in 2023 and is anticip.....
SynopsisBuparlisib is an orally bioavailable and selective pan-class I phosphatidylinositol-3 kinase (PI3K) inhibitor. The global Buparlisib market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during t.....
SynopsisWortmannin is a potent, selective, cell-permeable and irreversible inhibitor of phosphatidylinositol 3-kinase (PI 3-kinase)which also potently inhibits polo-like kinase 1. The global Wortmannin market was valued at US$ million in 2023 and is anticipated .....
SynopsisBerzosertib is an inhibitor of ataxia-telangiectasia mutated (ATM) Rad3-related protein kinase (ATR). The global Berzosertib (VE-822) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during .....
SynopsisSalubrinal is a selective Inhibitor of eIF2α dephosphorylation, inhibiting global protein translation. Salubrinal is a specific inhibitor of ER Stress induced apoptosis. The global Salubrinal market was valued at US$ million in 2023 and is anticipated to.....
SynopsisTolcapone is a reversible inhibitor of catechol-O-methyltransferase. The global Tolcapone market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030. North A.....
SynopsisLumiracoxib is a novel, selective COX-2 inhibitor with IC50 and Ki of 0.14 μM and 0.06 μM, exhibits 515-fold selectivity over COX-1. The global Lumiracoxib market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessi.....
SynopsisCenicriviroc is an experimental drug candidate for the treatment of HIV infection.Cenicriviroc is an inhibitor of CCR2 and CCR5 receptors, allowing it to function as an entry inhibitor which prevents the virus from entering into a human cell. The global .....
